Zweig-DiMenna Associates’s AbbVie ABBV Stock Holding History

Zweig-DiMenna Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,300	Closed	-$218K	–	140
2018 Q1	$218K	Sell	2,300 -100,474	-98%	-$11M	0.02%	129
2017 Q4	$9.94M	Buy	+102,774	New	+$9.69M	1.08%	35
2016 Q1	–	Sell	-56,190	Closed	-$3.33M	–	173
2015 Q4	$3.33M	Sell	56,190 -87,150	-61%	-$5.02M	0.17%	116
2015 Q3	$7.8M	Sell	143,340 -122,612	-46%	-$7.98M	0.34%	88
2015 Q2	$17.9M	Buy	+265,952	New	+$17.4M	0.99%	43
2014 Q3	–	Sell	-158,100	Closed	-$8.78M	–	260
2014 Q2	$8.92M	Buy	+158,100	New	+$8.29M	0.41%	78
2013 Q4	–	Sell	-208,416	Closed	-$9.32M	–	247
2013 Q3	$9.32M	Sell	208,416 -375,799	-64%	-$16.7M	0.38%	101
2013 Q2	$24.2M	Buy	+584,215	New	+$25.6M	0.98%	25

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Zweig-DiMenna Associates's ABBV Position: Q2 2018 in Review

Zweig-DiMenna Associates sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 2,300 shares — an estimated $218K sold.

Zweig-DiMenna Associates first reported a position in ABBV in Q2 2013 and held it in 8 quarters. The position peaked at $24.2M in Q2 2013. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Zweig-DiMenna Associates reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
Zweig-DiMenna Associates sold 2,300 AbbVie shares in Q2 2018, an estimated $218K.
Zweig-DiMenna Associates first reported a position in AbbVie in Q2 2013 and held it in 8 quarters.
Zweig-DiMenna Associates's AbbVie position peaked at $24.2M in Q2 2013.
1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2018, filed 1 Aug 2018.